AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle

AsymBio, a subsidiary of Asymchem Group , announced that it has established integrated technology platforms spanning the full biopharmaceutical development lifecycle. Through its end-to-end service capabilities, the company provides streamlined, integrated workflows from early development to commercial manufacturing.

AsymBio is a technology-driven biopharmaceutical CDMO focused on accelerating innovation through integrated development and manufacturing services for clients. Key platforms include:

  1. AmigoCHO™ Cell Line Development Platform — Supports high-titer, high-quality, and stable clones development, including cell pool establishment, expansion, clone selection.
  2. Upstream Process Development Platform — Covers optimization, scale-up, and characterization, supporting workflows from preclinical material preparation and IND/BLA-enabling development technology transfer; timelines can be shortened to as little as 9 weeks.
  3. Downstream Process Development Platform — Accelerates purification development to improve purity and yield and reduce impurities, including chromatography / filtration development, tech transfer, scale-up, and characterization.
  4. Conjugation Toolbox — Enables rapid development and optimization across bioconjugate modalities (e.g., ADCs, RDCs, AOCs, APCs) supporting cysteine/ lysine conjugation, enzymatic methods, engineered cysteine approaches, glyco-remodeling, and interchain cysteine re-bridging. The Conjugation Toolbox was shortlisted in the "Best ADC Platform Technology" category at the 2025 World ADC Awards.
  5. IMPACT Drug Product Development Platform — Delivers indication-, molecule-, and phase-accountable drug product development, supporting high-concentration, lyophilized, liquid, and frozen-liquid presentations, with formulation and process solutions for complex and high-potency biologics.
  6. Payload-Linker CMC Development Platform — Offers multiple payload and linker options (e.g., Auristatin, Maytansine, PBD dimer; peptide/PEG/sugar linkers) backed by extensive CMC experience, supporting more than 70 IND and 13 NDA projects.
  7. Comprehensive Analytical Platform — Provides analytical method development and in-depth product characterization, covering critical quality attributes across the product lifecycle, and comprising the Physicochemical Platform, Mass Spectrometry Platform, and Bioassay Platform.

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers from Pharmaceutical Outsourcing - all delivered right to your inbox! Sign up now!

  • <<
  • >>

Join the Discussion